Home
Alexion

Alexion Market Share Analysis for November 2025

Alexion Pharmaceuticals, a subsidiary of AstraZeneca, is a pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases.

Health > Biotechnology and Pharmaceuticals

Domainalexion.com

Year Founded1992

Employees1001 - 5000

Annual Revenue> $1B

Alexion

Alexion (including company regionals)

alexion.com

See more website traffic and engagement information

Alexion Revenue up to November 2025 is > 1B

revenue generated by Alexion top domains

Alexion top domains revenue over 3 years

Revenue for Alexion top domains

alexion.com> 1B

See more with Sales Intelligence

Total visits to Alexion's top domains

Understand Alexion market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

alexion.com54.9K

See more with Sales Intelligence

Avg. visit duration in Alexion's top domains

Analyze Alexion engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

alexion.com00:02:16

See more with Sales Intelligence

Avg. pageviews on Alexion's top domains

See how Alexion keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

alexion.com3.59

See more with Sales Intelligence

Alexion top competitors by domain

Top similar sites in November 2025, ranked by their affinity

takedaoncology.comCompany NameTakeda OncologyEmployees1001 - 5000HQUnited States, Massachusetts, CambridgeAnnual revenue$200M - $500MTotal visits10.8KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Alexion

These are the website technologies, by industry, used by Alexion top domains

Audio Video Media (4)

VideoJS

Content Management System (4)

Web Dot Com

Email Services (4)

G Suite

Advertising (3)

DoubleClick

More Technologies

11

See all

News & Signals from Alexion

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsAlexion Pharmaceuticals, Inc. is developing NI009 for AL amyloidosis.Alexion (astrazeneca) and Neurimmune expand alliance to develop NI009 for AL amyloidosis.

NewsAlexion Pharmaceuticals, Inc. is developing NI009.Neurimmune has expanded its transthyretin amyloid cardiomyopathy (ATTR-CM) collaboration with Alexion (an AstraZeneca company) by entering into an exclusive global collaboration and license agreement to develop NI009, a preclinical human monoclonal antibody designed to target and deplete lambda light chain fibrils and deposits from affected tissues and organs in light chain (AL) amyloidosis.

NewsAlexion Pharmaceuticals, Inc. receives award winner of the 'Customer Innovation Award.LIMERICK, Ireland - May 20, 2025 - Alexion Pharmaceuticals, Inc., was awarded winner of the 'Customer Innovation Award' at the inaugural 'Kneat Innovation Awards' held during VALIDATE 2025 conference in Boston April 30 - May 1.